LGND News Alert Ligand Pharmaceuticals Inc (LGND) 51.79 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ligand Pharmaceuticals Inc (LGND) 51.79 $LGND

Glaxo submits sNDA for Promacta expanded label
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 10:48AM CST

LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)

Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta(R)
Business Wire - Mon Dec 22, 8:20AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration for eltrombopag (Promacta), seeking an additional indication in pediatric patients six years old and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)

Update: Ligand Wins EU Approval For Duavive
Trevor Lowenthal - at Seeking Alpha - Sun Dec 21, 9:02AM CST

PFE: 31.42 (-0.03), LGND: 51.79 (+1.22)

Ligand earns milestone payment on EU approval of Duavive
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:48AM CST

PFE: 31.42 (-0.03), LGND: 51.79 (+1.22)

Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE(R) (Conjugated Estrogens/Bazedoxifene) for Treatment of Estrogen Deficiency Symptoms in Postmenopausal Women with a Uterus
Business Wire - Fri Dec 19, 10:30AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Pfizer has received EU marketing authorization for DUAVIVE(R) (conjugated estrogens/bazedoxifene (BZA/CE)) from the European Commission. In the EU, DUAVIVE(TM) is indicated for the treatment of estrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. Ligand will be entitled to a milestone payment following Pfizer obtaining pricing of DUAVIVE(R) in a major European market.
LGND: 51.79 (+1.22)

Ligand Pharmaceuticals: Investor Day Highlights The Big 6, All Undervalued Catalysts
Chris Katje - at Seeking Alpha - Mon Nov 24, 8:04AM CST

LGND: 51.79 (+1.22)

Ligand Provides Highlights from Today's Analyst Day Event
Business Wire - Tue Nov 18, 10:41AM CST
At an Analyst Day event held earlier today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the financial leverage in its business model, revenue growth opportunities and its portfolio of partnered assets and unpartnered development programs, as well as its Captisol formulation technology and its financial outlook through 2017.
LGND: 51.79 (+1.22)

Ligand Pharmaceuticals Shares Up 17.2% Since SmarTrend's Buy Recommendation (LGND)
Comtex SmarTrend(R) - Tue Nov 18, 9:44AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 1 month, Ligand Pharmaceuticals has returned 17.21% as of today's recent price of $57.25.
LGND: 51.79 (+1.22)

Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:00PM CST
Ligand Pharma (LGND) announced the submission of a Marketing Authorisation Application to the European Medicines Agency by its partner GlaxoSmithKline for Revolade.
LGND: 51.79 (+1.22), ILMN: 186.22 (+2.72), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48)

Glaxo applies for Revolade label expansion in Europe
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:01AM CST

LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)

Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade(TM) (eltrombopag)
Business Wire - Wed Nov 12, 8:15AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for Revolade(TM) (eltrombopag), seeking an additional indication for the treatment of adult patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).
LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)

Shares of LGND Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 11, 9:22AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 4 weeks, Ligand Pharmaceuticals has returned 13.91% as of today's recent price of $55.64.
LGND: 51.79 (+1.22)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CNAT: 6.84 (+0.17), MRK: 57.46 (+0.25), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST

JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CNAT: 6.84 (+0.17), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)

Post Earnings Update: Ligand Pharmaceuticals Has Sunk 0.5% Lower in Past 2 Weeks (LGND)
Comtex SmarTrend(R) - Mon Nov 10, 11:52AM CST
When Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings 14 days ago on October 27th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $14.9 million. The company actually reported EPS of $0.06 on sales of $15.0 million, missing EPS estimates by $0.27 and matching revenue estimates. Shares of Ligand Pharmaceuticals have slipped from $54.23 to $53.94, representing a loss of 0.5%, since the company reported earnings 14 days ago.
LGND: 51.79 (+1.22)

Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST

JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), CNAT: 6.84 (+0.17), MRK: 57.46 (+0.25), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)

Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST

JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), CNAT: 6.84 (+0.17), MRK: 57.46 (+0.25), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)

Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST

JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), CNAT: 6.84 (+0.17), MRK: 57.46 (+0.25), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)

Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST

JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CNAT: 6.84 (+0.17), MRK: 57.46 (+0.25), LGND: 51.79 (+1.22), RGLS: 14.78 (+0.24), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 64

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 137

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 48

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 134

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 5

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading

Top 5 Most Recently Viewed Articles

Forian Inc.'s Key Participation in ROTH MKM Annual Event

Updated Category News Views 92

Forian Inc. Engages at ROTH MKM Technology Event In a significant move within the technology sector, Forian Inc. (Nasdaq: FORA) is preparing for participation in the prestigious ROTH MKM 13th Annual Technology Event. The event promises an engaging platform for discussions surrounding technological advancements and investment opportunities. Who Will Represent Forian Inc.?...

Continue Reading
Davidson Kempner Capital Management Updates Direct Line Holdings

Updated Category News Views 202

Introduction to the Disclosure This article provides an overview of a significant disclosure regarding holdings in Direct Line Insurance Group PLC by Davidson Kempner Capital Management LP. As a major financial actor, Davidson Kempner plays a critical role in the financial ecosystem, particularly in how it approaches its investments and holdings. Key Information on...

Continue Reading
Uncovering Dropbox's Unique Marketing Strategies for Success

Updated Category News Views 360

Drew Houston’s Key Marketing Insights Dropbox (NASDAQ: DBX) has transformed from a simple file storage service into a multibillion-dollar enterprise, largely due to the strategic marketing insights shared by CEO Drew Houston. During a notable event at Stanford University, he discussed two crucial hacks that have led to a surge of paying customers. The core idea is...

Continue Reading
22nd Century's Transformation: Debt Erased, Growth Ahead

Updated Category News Views 229

22nd Century Group Transforms with Debt-Free Balance Sheet 22nd Century Group, Inc. (NASDAQ: XXII) has made significant strides in its financial stability by completely eliminating $3.9 million in senior secured debt. This remarkable feat not only lowers their ongoing cash needs but resets the financial landscape for the company, enabling them to redirect resources...

Continue Reading
Empowering QUBT Shareholders: Your Rights and Legal Options

Updated Category News Views 170

Understanding Your Rights as a Shareholder of Quantum Computing Inc. As a shareholder of Quantum Computing Inc. (NASDAQ: QUBT), it's essential to be aware of your rights regarding the ongoing legal issue facing the company. You may have heard of a recent class action lawsuit aimed at Quantum Computing, and it's vital to understand how this could impact you as an investor....

Continue Reading